Advertisement
ALEC vs ARCT
Which Stock Would AI Choose? Alector (ALEC) vs. Arcturus Therapeutics (ARCT) Stock Comparison
Key Takeaways
- Alector (ALEC) is a clinical-stage biotech pivoting toward its "Brain Carrier" blood-brain-barrier delivery platform after a late-stage trial failure and a major workforce reduction.
- Arcturus Therapeutics (ARCT) is an mRNA (messenger RNA) medicines company refocusing on rare liver and respiratory diseases, backed by positive interim data and new partnerships.
- Both stocks have rallied in 2026, but their drivers differ: ALEC has benefited from partnership validation, while ARCT has been lifted by clinical progress.
- ARCT carries a more constructive analyst consensus (Strong Buy), while ALEC faces mixed ratings after its pipeline reset.
- Cash runways differ meaningfully, with ARCT funded beyond 2028 and ALEC into 2027, shaping near-term risk profiles.
Introduction
Investors comparing ALEC and ARCT are weighing two clinical-stage biotechnology companies that have each undergone strategic resets in recent months. Both trade in a similar market-capitalization range, burn cash while advancing drug pipelines, and derive most of their value from future clinical outcomes rather than current revenue. This stock comparison is most relevant to investors and traders who follow the biotech sector, understand binary clinical catalysts, and want to assess relative performance, market positioning, and risk across two companies at very different stages of their scientific narratives.
ALEC Overview and Recent Performance
Alector, Inc. is a clinical-stage biotechnology company developing therapies for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and frontotemporal dementia (FTD). Recent market activity has been shaped by a significant strategic pivot. After its Phase 3 INFRONT-3 trial of latozinemab in FTD failed to meet its goals, the company terminated that program and reduced its workforce by roughly 49%, shifting from a late-stage developer toward an earlier-stage, platform-driven model.
Sentiment has since been mixed. The stock has gained strongly year to date in 2026, supported in part by a licensing agreement with Genentech around AL050, an engineered enzyme therapy delivered via Alector's "Brain Carrier" technology. The deal included an upfront payment reported at $100 million, with additional milestone potential, and has extended the company's cash runway. However, a separate Phase 2 trial (PROGRESS-AD) was discontinued after a futility analysis, and analysts remain divided, with some maintaining cautious ratings while others cite the platform's external validation. Alector reported approximately $206.5 million in cash and investments as of the end of the first quarter of 2026, funding operations into 2027.
ARCT Overview and Recent Performance
Arcturus Therapeutics Holdings Inc. is a messenger RNA (mRNA) medicines company focused on liver and respiratory rare diseases. It developed KOSTAIVE, the first self-amplifying mRNA (sa-mRNA) COVID-19 vaccine to receive approval, and is now redirecting resources away from vaccines toward its rare-disease pipeline. Its leading programs include ARCT-032 for cystic fibrosis (CF) and ARCT-810 for ornithine transcarbamylase (OTC) deficiency, a rare metabolic disorder.
Recent market activity has been broadly positive. The stock has advanced substantially in 2026, supported by encouraging interim Phase 2 data for ARCT-810 and the introduction of LUNAR 2.0, a next-generation delivery platform. The company also announced a collaboration with Thermo Fisher Scientific to support Phase 3 development of ARCT-032 and agreed to acquire myNEO, a computational biology firm, to strengthen its AI and mRNA design capabilities. Arcturus reported roughly $213.4 million in cash as of the end of the first quarter of 2026, with a runway extending beyond the second quarter of 2028. Analyst sentiment is notably constructive, with a consensus Strong Buy rating and several recent price-target increases.
Trending AI Robots
For traders seeking a more systematic approach to stock selection, Tickeron's Trending AI Robots page highlights AI-powered trading bots curated for current market conditions. Tickeron hosts hundreds of AI Trading Bots that collectively trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance track record, and set of securities. Because not every bot suits every market environment, only the most relevant and consistently strong performers earn a place in this curated section, helping users filter signal from noise. Whether you follow biotech catalysts or broader momentum strategies, exploring these quantitative tools can add a data-driven layer to your decision-making process.
Head-to-Head Comparison
The two companies operate in different corners of biotechnology. Alector is concentrated in neurodegeneration and depends heavily on the validation of its delivery platform after a late-stage setback, leaving it with a more speculative, earlier-stage profile. Arcturus spans multiple rare-disease programs with more advanced clinical catalysts and a stronger consensus view from Wall Street.
On financial positioning, Arcturus holds a longer cash runway and a more diversified set of near-term milestones, while Alector's runway is shorter and its valuation is tied more directly to partnership economics and platform potential. Risk profiles also differ: Alector carries the residual uncertainty of a recent pipeline reset, whereas Arcturus faces the challenge of replacing declining collaboration revenue as it transitions away from vaccine development. In terms of market sentiment, both names have outperformed the broader market in 2026, but ARCT's advance has been more consistently supported by data readouts and analyst upgrades, while ALEC's move reflects a sharper, deal-driven repricing.
Tickeron AI Verdict
Based on observable factors such as trend consistency, the density of upcoming catalysts, analyst positioning, and balance-sheet stability, Tickeron's AI would likely favor ARCT over ALEC in the current environment. Arcturus combines a longer cash runway, a more constructive analyst consensus, and multiple near-term clinical milestones with a steadier upward trend. Alector's platform story is compelling but remains earlier-stage and more dependent on future partnering events. This is a probabilistic, data-driven assessment rather than a definitive claim, and relative positioning could shift quickly as new clinical data and corporate developments emerge.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALEC is a Hold and ARCT is a StrongBuy.
ALEC sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for ALEC moved above the 200-day moving average on September 28, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +7.07% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALEC advanced for three days, in 217 of 259 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALEC as a result. In 86 of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The Moving Average Convergence Divergence Histogram (MACD) for ALEC turned negative on October 22, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 35 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
ALEC moved below its 50-day moving average on October 13, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ALEC crossed bearishly below the 50-day moving average on September 25, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALEC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for ALEC entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-20.495) is normal, around the industry mean (3.043). P/E Ratio (-1.679) is within average values for comparable stocks, (-1.361). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (15.060) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 55 (best 1 - 100 worst), indicating steady price growth. ALEC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 75 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALEC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
ARCT in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 16, 2026
ARCT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 28 of 32 cases where ARCT's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +6.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARCT advanced for three days, in 229 of 280 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 25, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARCT as a result. In 74 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
ARCT moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ARCT crossed bearishly below the 50-day moving average on October 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARCT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for ARCT entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.628) is normal, around the industry mean (3.043). P/E Ratio (-2.955) is within average values for comparable stocks, (-1.361). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (23.364) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. ARCT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARCT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
ALEC | ARCT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 46 | 77 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 8 Undervalued | 33 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 98 | |
PRICE GROWTH RATING 1..100 | 55 | 39 | |
P/E GROWTH RATING 1..100 | 75 | 94 | |
SEASONALITY SCORE 1..100 | 90 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ALEC's Valuation (8) in the Biotechnology industry is in the same range as ARCT (33) in the Pharmaceuticals Major industry. This means that ALEC’s stock grew similarly to ARCT’s over the last 12 months.
ALEC's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ARCT (100) in the Pharmaceuticals Major industry. This means that ALEC’s stock grew similarly to ARCT’s over the last 12 months.
ARCT's SMR Rating (98) in the Pharmaceuticals Major industry is in the same range as ALEC (100) in the Biotechnology industry. This means that ARCT’s stock grew similarly to ALEC’s over the last 12 months.
ARCT's Price Growth Rating (39) in the Pharmaceuticals Major industry is in the same range as ALEC (55) in the Biotechnology industry. This means that ARCT’s stock grew similarly to ALEC’s over the last 12 months.
ALEC's P/E Growth Rating (75) in the Biotechnology industry is in the same range as ARCT (94) in the Pharmaceuticals Major industry. This means that ALEC’s stock grew similarly to ARCT’s over the last 12 months.
| ALEC | ARCT | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 1 day ago 76% | 1 day ago 80% |
| Momentum ODDS (%) | 1 day ago 87% | 1 day ago 90% |
| MACD ODDS (%) | 1 day ago 88% | N/A |
| TrendWeek ODDS (%) | 1 day ago 87% | 1 day ago 86% |
| TrendMonth ODDS (%) | 1 day ago 86% | 1 day ago 84% |
| Advances ODDS (%) | 5 days ago 84% | 4 days ago 82% |
| Declines ODDS (%) | 3 days ago 86% | 1 day ago 88% |
| BollingerBands ODDS (%) | N/A | 1 day ago 88% |
| Aroon ODDS (%) | 1 day ago 82% | 1 day ago 87% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALEC’s FA Score shows that 1 FA rating(s) are green while ARCT’s FA Score has 1 green FA rating(s).
- ALEC’s FA Score: 1 green, 4 red.
- ARCT’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALEC’s TA Score shows that 3 TA indicator(s) are bullish while ARCT’s TA Score has 3 bullish TA indicator(s).
- ALEC’s TA Score: 3 bullish, 6 bearish.
- ARCT’s TA Score: 3 bullish, 5 bearish.
Price Growth
ALEC (@Biotechnology) experienced а -0.54% price change this week, while ARCT (@Biotechnology) price change was -4.84% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +1.24%. For the same industry, the average monthly price growth was -16.30%, and the average quarterly price growth was -16.78%.
Reported Earning Dates
ALEC is expected to report earnings on Nov 05, 2026.
ARCT is expected to report earnings on Nov 09, 2026.
Industries' Descriptions
@Biotechnology (+1.24% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| FLAX | 33.62 | 0.20 | +0.60% |
| Franklin FTSE Asia ex Japan ETF (FLAX) | |||
| MIGO | 29.48 | N/A | N/A |
| MIG Core ETF (MIGO) | |||
| BITY | 26.93 | -0.05 | -0.20% |
| Amplify Bitcoin 2% Monthly Option Income ETF (BITY) | |||
| BFEB | 53.93 | -0.22 | -0.40% |
| Innovator U.S. Equity Buffer ETF - February (BFEB) | |||
| DUHP | 42.14 | -0.37 | -0.87% |
| U.S. High Relative Profitability Portfolio: ETF Class Shares (DUHP) | |||